# AI Can Now Prescribe Medicine Without a Doctor (Utah Just Made It Legal)

Source: https://qvantx.com/insights/ai-can-now-prescribe-medicine-without-a-doctor-utah-just-made-it-legal/
Author: Ani Björkström — QvantX Sweden AB, Stockholm
Published: 2026-10-08
Updated: 2026-11-08
Video: https://www.youtube.com/watch?v=T2c6QXmSYUs (4 min)
Topic: AI Tools

License: free to quote and cite with attribution to https://qvantx.com

---
_AI REGULATION_

## Why Does Utah's AI Prescription Ruling Matter for Financial Services Regulators?

#### Key takeaways

- Utah's Office of Artificial Intelligence Policy approved a staged-autonomy model for AI decision-making — intensive human review that tapers to spot-checks over time — a template other regulated sectors, including financial services, could adapt for AI-driven credit, advice, or underwriting decisions.

- As of 5 October 2026, Utah authorised Nolla Derm, an app from Nolla Health, to issue brand-new prescriptions for mild-to-moderate acne without a physician reviewing every case in real time — the first such authorisation by a US state regulator.

- Nolla Health reports that licensed clinicians agreed with the AI's treatment recommendation in approximately 96% of recent real-world cases, even as oversight shifts from full pre-approval to sampling-based review.

Ani Björkström, the Stockholm-based AI consultant behind the YouTube channel "Ani Björkström | AI for Finance," breaks down a healthcare regulatory decision with a structure finance professionals will recognise immediately: a government sandbox granting an AI system expanding autonomy in stages, with human review decreasing as trust in the system's track record grows. The video is aimed at anyone evaluating how regulators might eventually treat AI systems that make consequential decisions without a human reviewing every case — a question just as live in lending, advice, and compliance as it is in medicine.

### What exactly did Utah authorise Nolla Derm to do?

Utah authorised Nolla Derm's AI to issue initial prescriptions — not refills — for topical acne medication, without requiring a physician to review every single case in real time. Utah residents aged 18 and older verify their identity with a government ID and a selfie, complete a short intake questionnaire, and submit a five-angle face scan; the company says the process takes about 10 to 15 minutes.

If the AI determines the case is mild to moderate acne meeting its criteria, it can prescribe from a fixed list: tretinoin, adapalene, clindamycin with benzoyl peroxide, benzoyl peroxide, and azelaic acid. Oral medications, isotretinoin, and severe acne cases are excluded from the AI's authority entirely. The pilot is priced at $4.99 per month.

### How does Utah's staged physician-oversight model work?

Oversight starts at its strictest and thins out as the program scales. In stage one, covering the first 100 patients, two licensed Utah physicians must independently review and approve every AI-generated prescription before it reaches the patient.

In later stages, review shifts first to post-issuance checking, then to sampling only a percentage of cases. Nolla Health states that clinicians agreed with the AI's recommendation in roughly 96% of recent real-world cases, with most disagreements being minor strength adjustments rather than changes to the treatment itself. The agreement also requires monthly reporting, adverse-event reporting within 24 hours, and third-party auditors — the accountability scaffolding regulators are using to justify reduced human review over time.

### What access gap is the regulator using to justify less human oversight?

Utah's dermatology access gap is the stated justification: state and company materials cite roughly 100,000 Utahns with active acne at any given time, of whom only about 10% ever see a dermatologist. The average wait for an appointment is reported at 61 days, nearly double the national median, and 11 Utah counties have no dermatologist at all; in-person visits can cost up to $300.

The video notes this is not a Utah-specific problem — more than 80% of US counties are considered healthcare deserts of some kind, affecting over 120 million people. The pattern worth watching for any regulated industry is that a severe access or cost gap is the argument regulators accept for granting an AI system expanding autonomy — the same logic could be applied anywhere access to a licensed professional is scarce or expensive.

### Who is liable, and could this spread to other states or sectors?

Liability and accountability questions remain unresolved and are still under discussion among physicians and regulators, according to the video. This is not Utah's first AI prescribing pilot: earlier in 2026, the state authorised a separate system, Doctronic, to handle prescription refills, which drew public criticism from members of the Utah Medical Licensing Board over patient safety and oversight levels. The Nolla Derm pilot goes further by allowing initial prescriptions, not just renewals.

Nolla Health has previously raised $4.5 million in funding, including from General Catalyst, and its app had already been downloaded more than 175,000 times across 44 states under an earlier model that still required clinician approval of every case. The open questions the video poses — whether staged review is safe enough, whether the 96% agreement rate holds as volume rises and human review falls, and how other states respond if outcomes look acceptable — are the same questions any regulator considering a similar sandbox for AI-driven financial decisions will eventually have to answer.

| Stage | What happens | Detail from the pilot |
|---|---|---|
| Patient intake | ID and selfie verification, questionnaire, five-angle face scan | Takes about 10-15 minutes; $4.99/month pilot price |
| Oversight stage 1 (first 100 patients) | Two licensed Utah physicians independently review and approve every AI prescription | Full pre-issuance human review |
| Oversight stage 2 | Post-issuance review | Prescription reaches patient before physician review completes |
| Oversight stage 3 | Sampling a percentage of cases | Lowest level of human review in the program |
| Reported outcome | Clinician agreement with AI recommendation | Approximately 96% in recent real-world cases; most disagreements were strength adjustments, not treatment changes |

#### FAQ

**Which drugs can Nolla Derm's AI actually prescribe?**

A fixed list of topical treatments only: tretinoin, adapalene, clindamycin with benzoyl peroxide, benzoyl peroxide, and azelaic acid, for adults 18 and older with mild to moderate acne. Oral medications, isotretinoin, and severe acne cases are excluded entirely.

**Is this the first time a US state has let an AI prescribe medicine?**

It is the first time a state has authorised an AI to issue an initial prescription. Earlier in 2026, Utah authorised a different system, Doctronic, to handle prescription refills, a program that drew criticism from the Utah Medical Licensing Board over safety and oversight.

**Who is liable if the AI prescribes the wrong treatment?**

According to the video, liability and accountability questions remain under discussion among physicians and regulators and have not been resolved. The program does require monthly reporting, adverse-event reporting within 24 hours, and third-party auditors as part of its agreement with the state.


## Full video transcript

Chapters: 0:00 Utah just let an AI write real prescriptions · 0:17 Not a refill — a brand new prescription · 0:30 How the Nolla Derm app works: ID, questionnaire, face scan · 0:45 Which acne drugs the AI can prescribe, and what's excluded · 1:08 4.99 a month, and the three stages of physician oversight · 1:36 Clinicians agreed with the AI in 96% of cases · 1:48 Utah's dermatology gap: 61-day waits, 11 counties with none · 2:13 80% of US counties are healthcare deserts · 2:26 Utah's AI sandbox and the Doctronic pilot doctors tried to stop · 2:54 What the agreement requires, and who is liable · 3:11 Nolla's $4.5M funding and 175,000 downloads in 44 states · 3:37 Three questions that decide what happens next · 3:57 What's your view?

[0:00] On October 5th, 2026, Utah became the first US state to authorize an artificial intelligence system to issue initial prescriptions without a doctor reviewing every case in real time. The system is limited to topical acne medications for mild to moderate cases. [music] This is not a refill program. It is the first time AI has been allowed to write a brand new prescription under a state regulatory agreement. The app is called NolaDerm, made by Nola Health. Utah residents 18 and older can download it, verify their identity with a government ID and selfie, complete a short intake questionnaire, and take a five-angle face scan. According to the company, the process takes about 10 to 15 minutes. If the AI determines the patient has mild to moderate acne and meets the criteria, it can generate a prescription from a fixed list of topical treatments only, including tretinoin, adapalene, clindamycin with benzoyl peroxide, benzoyl peroxide, and azelaic acid.

[1:00] Oral medications, isotretinoin, and severe acne are excluded. The pilot price is $4.99 per month. There is staged physician oversight. [music] In the first stage, covering the first 100 patients, two licensed Utah physicians must independently review and approve every AI-generated prescription before it reaches the patient. In later stages, the level of real-time review decreases, moving first to post-issuance review, and eventually to sampling a percentage of cases. Nola Health states that licensed clinicians have agreed with the AI's treatment recommendations in approximately 96% of recent real-world cases. Most disagreements were minor adjustments in strength rather than changes to the treatment itself.

[1:50] Utah has significant access gaps in dermatology. The company and state materials cite roughly 100,000 people in Utah with active acne at any given time with only about 10% ever seeing a dermatologist. The average wait for an appointment is reported at 61 days, nearly double the national median. 11 counties have no dermatologist at all. In-person visits can cost up to $300. More than 80% of US counties are considered healthcare deserts of some kind affecting over 120 million people. This pilot is part of Utah's AI sandbox program which allows temporary regulatory relief for controlled testing of AI systems under state oversight. Earlier in 2026, Utah authorized a separate AI system, Doctronic, [music] to handle certain prescription refills.

[2:44] That program drew public criticism from members of the Utah Medical Licensing Board who raised concerns about patient safety and the level of clinical oversight. The Nola pilot goes further by allowing initial prescriptions, not only renewals. The agreement includes monthly reporting requirements, adverse event reporting within 24 hours, and third-party [music] auditors. Liability and accountability questions remain under discussion among physicians and regulators. Nola Health previously raised $4.5 million in funding including from General Catalyst. Its app had already been downloaded by more than 175,000 44 states under a model that still required clinician approval. The Utah pilot is the first time the company has been authorized to let the AI issue the initial prescription under the staged oversight described earlier.

[3:39] The core factual questions this raises are straightforward. Does the [music] staged review model provide sufficient safety for low-risk topical acne treatment? Will the reported 96% agreement rate hold as the volume increases and human review decreases, and how will other states respond if the pilot data shows acceptable outcomes? Those are the documented facts as of today. What is your view on allowing AI to issue initial prescriptions under this kind of staged oversight? Leave your thoughts in the comments.